BioSpace News Archive

Bio-Rad Laboratories, Inc. announced that it had received an expected notice from the New York Stock Exchange stating that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual due to the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

Sydys Corporation announced that on March 25, 2019, the Company voluntarily filed a Form 15 with the United States Securities and Exchange Commission to voluntarily deregister its common stock and suspend its reporting obligations under the Securities Exchange Act of 1934, as amended.

On Thursday, March 28, the American Diabetes Association®, along with hundreds of people living with diabetes, caregivers, health care providers, and researchers will meet with members of Congress to ask them to make diabetes a national priority.

New England Journal of Medicine Study Reports Harmful Side Effects of Daily Aspirin

A third party press release was issued stating that the EMA issued an approval for the conditional Marketing Authorization Application for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia.

Ascentage Pharma announced that research results of its pipeline of small molecule therapeutics will be presented at the 2019 American Association for Cancer Research annual meeting in Atlanta, March 29-April 3, 2019.

Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is delighted to announce that Dr Thomas Ramdahl will join Clarity’s Board.

Breakthrough Herbal Remedy Combines Cannabinoids From THC-Free Cannabis and A Wide Array Of Non-Cannabis Plants To Manage Occasional Pain

Second annual list helps identify best practices and accelerate progress for community health across the country

Phase 3 BOSTON clinical studies will evaluate Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), the first potential therapy for Bronchiolitis Obliterans Syndrome (BOS)